Feb 26, 2019 · 35m · a16z
a16z Podcast | Connecting Hearts, Bodies, and Networks to Cure Cancer
Dr. Amy Abernethy · 15m spoken Christina Lopez · 10m spoken Jorge Conde · 6m spoken Sonal Chokshi · 1m spoken
0:00 / 0:00
▶ Watch on YouTube →
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In this episode of the a16z Podcast, experts discuss how comparative canine oncology, advanced veterinary data networks, and precision medicine can transform cancer treatment for both pet dogs and human patients. The conversation also provides strategic frameworks for biotech founders on product execution, data monetization, and cross-functional leadership.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. The host holds 3.4% of the talking time here. How this is scored →
The host as informed peer 2.9 Guest teaching 3.2 Guest disagreement 0.7 The host pushing back 0.1
speaking balance: gold is the host, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 31:58 Advisors pushing back on perfection
Christina describes internal team members and external academic advisors challenging the company's rollout timing by demanding biological perfection and complete proof upfront.
Hardest push from the host ▶ 30:48 Challenging the tendency to over-engineer v1.0Jorge actively pushes back against the temptation to continuously expand product scope, urging founders to resist over-engineering version 1.0 when existing solutions are rudimentary.
Biggest teaching moment ▶ 6:05 Conserved canine biology versus mouse modelsDr. Abernethy educates the host on how canine cancer pathways conserve human cell biology far better than mouse models, transforming how oncology go-no-go decisions are evaluated.
The host holds their own ▶ 27:06 Synthesizing marketplace network frameworksJorge showcases extensive venture knowledge by synthesizing One Health's complex bio data model into the canonical tech marketplace adage 'come for the tools, stay for the network'.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | The host as informed peer | Guest teaching | Guest disagreement | The host pushing back | Why |
|---|---|---|---|---|---|---|
| Evolutionary Link and Environmental Factors in Canine Cancer | 1 | 4 | 1 | 0 | Host Jorge Conde asks introductory questions about dog cancer origins and diagnostic procedures. Guest Christina Lopez educates the host on canine breeding history, secondhand environmental exposures like golf course pesticides, and behavioral signs observed by owners. | |
| Biological Similarities Between Dog and Human Oncology | 1 | 5 | 1 | 0 | Jorge asks baseline questions regarding dog melanoma and comparative oncology models. Dr. Amy Abernethy explains that canine cellular pathways conserve significantly more human biology than engineered mouse models do. | |
| Spontaneous Disease vs. Engineered Mouse Models | 2 | 4 | 1 | 0 | Jorge accurately synthesizes the core distinction between forced mouse models and spontaneous canine disease. Christina and Dr. Abernethy expand on how natural immune system interactions in dogs create a real-world living laboratory. | |
| Dog Electronic Health Records and the Absence of 'Doggy HIPAA' | 2 | 4 | 1 | 0 | Jorge asks mechanically how veterinary health records are aggregated and whether dog privacy laws exist. Dr. Abernethy explains that veterinary electronic health records exist and the lack of regulatory hurdles like HIPAA accelerates research aggregation. | |
| Accelerated Lifespans and Early Cancer Intervention | 3 | 3 | 1 | 0 | Jorge brings up human genetic markers like BRCA to ask if dog equivalents exist. Christina outlines known BRAF mutations in canine bladder cancer while noting the severe shortage of veterinary oncologists nationwide. | |
| Precision Medicine and Next-Gen Sequencing for Dogs | 3 | 2 | 1 | 0 | Jorge helps frame the company's product positioning by drawing parallels to human diagnostic platforms, coining it 'Foundation Medicine for dogs'. Christina details their next-gen sequencing panel and actionable mutation reports. | |
| Combination Therapies, Data Network Effects, and Virtual Trials | 4 | 2 | 0 | 0 | Jorge demonstrates startup domain knowledge by identifying canonical data network effects in One Health's model. Dr. Abernethy builds on this by explaining how networked veterinary clinics enable virtual clinical trials for human cross-translation. | |
| Sequenced Product Roadmap and Company Building | 5 | 2 | 0 | 0 | Jorge cites the classic tech startup paradigm 'come for the tools, stay for the network' to articulate One Health's dual-product model. Dr. Abernethy details sequential product development lessons drawn from her Flatiron Health experience. | |
| Advice for Founders on Short-Term Goals vs. Long-Term Vision | 2 | 5 | 1 | 0 | Jorge prompts the guests for founder advice regarding startup execution pitfalls. Dr. Abernethy provides a structured advisory framework on balancing 3-to-6-month product milestones against long-term 10-year scientific goals. | |
| Managing Product Scope and Fostering Cross-Functional Teams | 6 | 1 | 0 | 1 | Jorge takes an active advisory role, warning against over-engineering initial product releases and offering concrete guidance on bridging cross-functional communication gaps between tech and bio hires. Christina warmly concurs with his framework. |
Statements from this episode (20)
Amy Abernethy Named Principal Deputy Commissioner of the FDA
“So first, our special guest is Amy Abernethy, who has been named the new principal deputy commissioner of the FDA, the U.S. Food and Drug Administration, pending ethics clearance.”
Lopez: Dog Breeds Living Near Golf Courses Suffer Higher Bladder Cancer Rates
“Certain breeds near golf courses have had actually bladder cancer, transitional cell carcinoma, it's actually an area of study.”
Lopez: Canine Genomics Lacks NIH Research Funding Compared to Mouse Models
“Veterinary medicine has not had the resources, and even from the NIH level, what the mouse has been very well characterized and studied, the dog really hasn't.”
Conde: Six Million Dogs Are Diagnosed With Cancer Yearly in the US
“Six million cases a year of diagnosed cancer in the United States in dogs.”
Dr. Abernethy: Dogs share more conserved biology with humans than mice do
“So there's much more conserved biology between dog and human than mouse and human.”
Abernethy: Testing cancer drugs in dogs saves tens of millions per drug
“The whole message that really I walked away from that conference with was that if we now embedded into the drug development process for human drug development a better understanding of how those drugs performed in dogs, we could save many tens of millions of d…”
Lopez: Spontaneous Canine Cancers Have Intact Immune Systems Missing in Mice
“Dogs that have natural disease, spontaneous disease, have an immune system also that's working, and that's a radical difference from the mice models that are much more engineered and sometimes don't have an immune system to have the cancer, and then the ones t…”
Lopez: Canine trials saved the development of lymphoma drug ibrutinib
“And you know the story of rebrutinib, a lymphoma drug that, you know, the dog and the human, and actually the evidence from the dog helped not just this company be alive, but the drug be alive”
Abernethy: Lack of pet HIPAA rules simplifies veterinary health data aggregation
“There's no doggy HIPAA. Now, we have to do the right thing by pets and pet owners, and we need to basically only think about using that information in a way that's good for society, for pets and pet owners. But that being said, many of the impediments, as we t…”
Christina Lopez: Canine cancer probability increases significantly after age five
“And if you correlate cancer with aging, the dogs after the age of even five, the probability of cancer goes way up.”
Lopez: Veterinary oncology relies on only 13 total cancer therapies
“The toolbox is probably 13 therapies in total that we were talking about with Cheryl London, one of our KOLs that's really top in canine oncology, total.”
Lopez: US has only 400 veterinary oncologists for six million dogs
“Not everyone can get to a vet oncologist, which there's only about three, 400 in the United States for, you know, think about six million dogs, three, 400, right?”
Lopez: 85% of dogs with bladder cancer carry V600E BRAF mutation
“85% of dogs with transitional cell carcinoma are BRAF positive, and it's V 600 E BRAF, very particular.”
Lopez: One Health built the first NGS panel for dogs
“We have the first next gen sequencing panel for dogs.”
Conde: Canine oncology exhibits canonical data network effects
“What you're describing here is sort of a canonical data network effect that the more dogs you treat in more combinations results in better information to treat more dogs with better combinations and so on and so forth. So the product gets in continuously bette…”
Abernethy: Health data platforms must serve clinical users before monetizing data
“So what we saw at Flatiron is you've got to make sure that you take care of oncologists and patients first, and have a mechanism to bring the data in, and then you can get the data ready To have secondary purposes. But if you have that out of order, you've act…”
Abernethy: Early bio startups shouldn't detail plans past six months
“Don't spend too much of your time and hear the details of exactly what I'm going to do in six months plus until you've got early data coming back.”
Abernethy: Scientific advisors struggle with early biotech's short-term focus
“Those advisors who are bringing that scientific advice to you, either in your company or as external advisors, are not going to understand why you're not doing all the things that you have to do for that seven year timeframe, because really what you've got to …”
Abernethy: Core FDA priorities will be evidence generation, personalized medicine, drug design
“When I'm at FDA, I will have a trans-FDA remit, so I will need to spend my time and energy working on the things that the FDA needs me to do, and I'm looking forward to learning more and more about that every day. But I know that I'll at least spend some of my…”